PRISM BioLab Co. LTD (206A) Stock Price & Analysis

206A Stock Chart & Stats

¥132.00¥2.00(1.54%)

At close: Oct 30 3:30 PM GMT+9

Day’s Range: JPY 129.00 - JPY 133.00
52-Week Range: JPY 125.00 - JPY 279.00
Previous Close: JPY 130.00
Volume: 305.30K
Average Volume (3M): 65.07K
Market Cap: JPY 4.89B
Enterprise Value: JPY 2.99B
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): ―
Beta: 0.98
Next Earnings: Nov 13, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Growth

The strong recent revenue expansion indicates that PRISM BioLab is generating greater commercial or partnering activity as its programs advance. If this growth persists, it can broaden the company’s funding base and improve operating leverage, although profitability remains unproven.

Debt-Free Balance Sheet

A debt-free balance sheet reduces mandatory financing costs and near-term solvency pressure while preserving flexibility to fund research and development. This gives PRISM BioLab more time to advance its drug programs and negotiate partnerships without the constraints associated with significant leverage.

Partnering-Based Drug Discovery Model

The partnering and licensing model can let PRISM BioLab monetize intellectual property through several potential payment streams while larger pharmaceutical partners support development. Successful collaborations could provide non-dilutive funding and create recurring royalty opportunities from commercialized medicines.

Bears Say

Persistent Unprofitability

Persistent EBIT and net losses show that the recent revenue rebound has not yet translated into a self-sustaining business. Continued losses can constrain internal investment, weaken shareholder value creation, and increase reliance on partnerships or external financing while programs mature.

Accelerating Cash Burn

Negative and volatile operating cash flow means PRISM BioLab is consuming cash while funding its research and development activities. The sharp 2025 free-cash-flow deterioration raises the risk that additional financing or partnership proceeds will be needed to sustain operations over the coming quarters.

Compressed Gross Margins

Gross-margin compression indicates that growth has not produced the same level of economic efficiency as earlier periods. Combined with deeply negative net margins, this weakens the quality of revenue expansion and makes future profitability dependent on cost control and better program economics.

PRISM BioLab Co. LTD News

PRISM BioLab’s Revenue Rises but Losses Deepen and Equity Shrinks

PRISM BioLab Co. LTD ( ($JP:206A) ) just unveiled an announcement. PRISM BioLab reported non-consolidated revenue of ¥369 million for the nine months to June 30, 2026, up 19.4% year

2M ago206A

PRISM BioLab to End Drug Discovery Library Agreement with Boehringer Ingelheim

PRISM BioLab Co. LTD ( ($JP:206A) ) has issued an update. PRISM BioLab announced that its research and license agreement with German pharmaceutical group Boehringer Ingelheim International will end on

5M ago206A

PRISM BioLab Widens Interim Loss, Cuts Equity and Withholds Full-Year Outlook

PRISM BioLab Co. LTD ( ($JP:206A) ) has shared an update. PRISM BioLab reported non-consolidated revenue of ¥253 million for the six months to March 31, 2026, a 15.8% year-on-year

5M ago206A

PRISM BioLab and Receptor.AI Team Up on AI-Driven Small-Molecule Drug Discovery

PRISM BioLab Co. LTD ( ($JP:206A) ) has shared an update. PRISM BioLab and Receptor.AI have signed a drug discovery collaboration to build an integrated, AI-navigated, physics-guided platform for designing

7M ago206A

PRISM BioLab Widens Quarterly Losses and Withholds Full-Year Guidance

PRISM BioLab Co. LTD ( ($JP:206A) ) has issued an announcement. PRISM BioLab reported first-quarter revenue of ¥132 million for the fiscal year ending September 30, 2026, a modest year-on-year

8M ago206A

PRISM BioLab and Talus Bioscience Collaborate on Novel Drug Discovery

The latest announcement is out from PRISM BioLab Co. LTD ( ($JP:206A) ). PRISM BioLab and Talus Bioscience have announced a collaboration to discover novel inhibitors for transcription factor and

10M ago206A

PRISM BioLab Reaches Milestone in Oncology Collaboration with Ono Pharmaceutical

PRISM BioLab Co. LTD ( ($JP:206A) ) just unveiled an announcement. PRISM BioLab Co., Ltd. has achieved an initial milestone in its drug discovery collaboration with Ono Pharmaceutical Co., Ltd.,

11M ago206A

PRISM BioLab Reports Increased Revenue Amid Financial Challenges

PRISM BioLab Co. LTD ( ($JP:206A) ) just unveiled an update. PRISM BioLab Co., LTD reported its non-consolidated financial results for the fiscal year ended September 30, 2025, showing a

11M ago206A

PRISM BioLab Ends Collaboration with Servier, Plans Future Partnerships

An update from PRISM BioLab Co. LTD ( ($JP:206A) ) is now available. PRISM BioLab Co., Ltd. announced the termination of its Collaboration & License Option Agreement with Servier, which

1y ago206A

206A FAQ

What was PRISM BioLab Co. LTD’s price range in the past 12 months?

PRISM BioLab Co. LTD lowest stock price was ¥125.00 and its highest was ¥279.00 in the past 12 months.

What is PRISM BioLab Co. LTD’s market cap?

PRISM BioLab Co. LTD’s market cap is ¥4.89B.

When is PRISM BioLab Co. LTD’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were PRISM BioLab Co. LTD’s earnings last quarter?

PRISM BioLab Co. LTD released its earnings results on Aug 14, 2026. The company reported -¥6.56 earnings per share for the quarter.

Is PRISM BioLab Co. LTD overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does PRISM BioLab Co. LTD pay dividends?

PRISM BioLab Co. LTD does not currently pay dividends.

What is PRISM BioLab Co. LTD’s EPS estimate?

PRISM BioLab Co. LTD’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PRISM BioLab Co. LTD have?

PRISM BioLab Co. LTD has 37,039,000 shares outstanding.

What happened to PRISM BioLab Co. LTD’s price movement after its last earnings report?

PRISM BioLab Co. LTD reported an EPS of -¥6.56 in its last earnings report. Following the earnings report the stock price went down -1.19%.

Which hedge fund is a major shareholder of PRISM BioLab Co. LTD?

Currently, no hedge funds are holding shares in JP:206A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description